KCA
Articles
- Page Path
- HOME > J Korean Cancer Assoc > Volume 32(5); 2000 > Article
-
Original Article
- Combination Chemotherapy with Cisplatin and Vinorelbine in Patients with Non-Small-Cell Lung Cancer
- Kee Won Kim, Suk Young Park, Ji Won Suhr, Seung Joon Kim, Dong Hoen Yang, Eun Hee Lee, Kyung Shick Lee
-
Journal of the Korean Cancer Association 2000;32(5): 911-917.
1Departments of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
2Departments of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
3Departments of Clinical Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
2Departments of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
3Departments of Clinical Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 2,934 Views
- 17 Download
- 0 Crossref
- 0 Scopus
Abstract
PURPOSE
To determine the therapeutic effect and toxicities of cisplatin and vinorelbine combination chemotherapy in patients with inoperable non-small-cell lung cancer.
MATERIALS AND METHODS
Between Jan 1998 and Dec 1999, 28 patients with inoperable non- small-cell lung cancer were treated with cisplatin and vinorelbine combination chemotherapy as induction treatment. A combination of vinorelbine 25 mg/m2 day 1,8 and cisplatin 60 mg/m2 day 1 were given and repeated every 3 weeks. Then we assessed response and toxicity according to WHO grades.
RESULTS
According to response criteria, there were 1 complete response, 12 partial response (42.9%), 12 stable disease (42.9%), and 3 progression (10.7%). The median survival was 12 months. According to toxicity grades, 24 grade 3 myelosuppression (24.7%), 12 grade 4 myelo suppression (10.7%), 6 grade 3 and 4 constipation (6.1%), and mild 7 (7.2%) thrombophlebitis were experienced in evaluable 97 cycles. There was no other clinically severe toxicity.
CONCLUSION
These results suggest that combination chemotherapy with cisplatin and vinorelbine in patients with inoperable non-small-cell lung cancer was effective and safe.
Cite- Related articles
-
- Clinical Effect of Endosonography on Overall Survival in Patients with Radiological N1 Non–Small Cell Lung Cancer
- Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non–Small Cell Lung Cancer
- The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
- A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
